GLP-1 Evidence

Drug profile

Dulaglutide: what the trials actually show

GLP-1 receptor agonist. Weekly injection.

Updated 2 min read 14 citations

Close view of the two eyepiece lenses of a binocular microscope
Shixart1985 · CC BY 2.0 · Wikimedia Commons

What the evidence supports

REWIND showed cardiovascular benefit in type 2 diabetes. Weight reduction is modest compared with semaglutide or tirzepatide. [1]

Not approved for weight management. Included because it is frequently encountered and frequently confused with the weight-management agents.

Evidence strength across the incretin drugs profiled Of the 6 incretin drugs and preparations profiled, this shows how many sit at each level of evidence, with Dulaglutide graded established. Established4 drugsPromising1 drugsPopular but weak1 drugs
Dulaglutide is graded established. The grade describes the quality of the trial evidence, not how well the drug will suit any individual — and the one entry graded "popular but weak" is there precisely because it is widely sold and never trialled. Grades assigned from trial programme and regulatory status.

What happens when you stop

This is the part of the picture most often left out. Withdrawal trials consistently show substantial weight regain within a year of stopping, and cardiometabolic markers drifting back with it [2]. That is not a failure of the drug — it is what treating a chronic condition with a drug looks like when the drug is removed.

The practical implication is that the decision to start is a decision about a long horizon, including cost and access over that horizon, rather than about a target weight.

Muscle mass

Rapid weight loss from any cause includes lean tissue, and the incretin trials are no exception. The proportion lost as lean mass appears broadly similar to other rapid-loss methods, but the absolute loss is larger because the total loss is larger. Adequate protein and resistance training are the interventions with evidence behind them, and both are within your control while taking the drug.

White film-coated tablets held in a blister strip
Cindy Shebley · CC BY 2.0 · Wikimedia Commons

Other drugs in this class

How much weight do people lose on dulaglutide?
REWIND showed cardiovascular benefit in type 2 diabetes. Weight reduction is modest compared with semaglutide or tirzepatide. Those are trial means; individual response varies widely and trial participants receive support that is part of the result.
What happens if I stop?
Most of the weight returns, typically within a year. Withdrawal trials are consistent on this and it is the single most important thing to understand before starting.
Does it cause muscle loss?
Rapid weight loss from any cause includes lean tissue. Protein intake and resistance training are the mitigations with evidence behind them.
Is a compounded version the same thing?
No. Compounded preparations are not the products that were trialled, dosing errors are documented, and some use salt forms never studied in humans.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  2. Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials Ciudin A, Sapin H, Fan L, et al. · Advances in therapy · 2026 · Meta-analysis DOIPubMed 41820778Full text
  3. Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis Naz F, Qaiser F, Mumtaz A, et al. · Medicine · 2026 · Meta-analysis DOIPubMed 42536519Full text
  4. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement Oprea AD, Ostapenko LJ, Sweitzer B, et al. · British journal of anaesthesia · 2025 · Systematic review DOIPubMed 40379536Full text
  5. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism: clinical and experimental · 2025 · Meta-analysis DOIPubMed 39719170
  6. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  7. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials Moiz A, Filion KB, Toutounchi H, et al. · Annals of internal medicine · 2025 · Systematic review DOIPubMed 39761578
  8. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  9. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary Diabetologia · 2024 · Clinical guideline DOIPubMed 38869512Full text
  10. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Moiz A, Levett JY, Filion KB, et al. · The American journal of cardiology · 2024 · Meta-analysis DOIPubMed 38679221
  11. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Journal of hepatology · 2024 · Clinical guideline DOIPubMed 38851997
  12. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024 · Systematic review DOIPubMed 38629387
  13. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Yao H, Zhang A, Li D, et al. · BMJ (Clinical research ed.) · 2024 · Meta-analysis DOIPubMed 38286487Full text
  14. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Stefanou MI, Theodorou A, Malhotra K, et al. · European stroke journal · 2024 · Meta-analysis DOIPubMed 38400569Full text